Navigation Links
Cord Blood America Provides Insight on Worldwide Research Using Umbilical Cord Blood Stem Cells to Treat Numerous Diseases
Date:10/24/2011

LAS VEGAS, Oct. 24, 2011 /PRNewswire/ -- Heart repair.  Bone repair.  Spinal cord injuries.  Hearing loss. Traumatic brain injury.  Cerebral Palsy.  Diabetes.  Alzheimer's.  Cystic Fibrosis.  Leukemia, Sickle cell disease and other blood disorders.  Immune and metabolic disorders.

"These diseases or group of diseases are either currently being treated and cured with umbilical cord blood stem cells or there is clinical research ongoing in the U.S. and worldwide to use cord blood stem cells in treatment procedures," said Dr. Geoffrey O'Neill, Cord Blood America Vice President, Operations.  Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI), is the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally.

"Umbilical cord blood stem cells have been used in more than 15,000 transplants worldwide to treat acute and chronic childhood leukemia. These stem cells have proven to be curative in treating sickle cell disease and other blood disorders and have been used to treat certain immune and metabolic disorders, 75 diseases in all," Dr. O'Neill explained.  "This makes banking stem cells at birth an insurance policy for the child."

"Scientists believe these stem cells from the umbilical cord are capable of differentiating into many other cell types within the body to form new tissue and even organs.  That is why there is ongoing research using these stem cells aimed at the  treatment of diseases or conditions that are currently incurable," Cord Blood America's executive explained.  These include:

  • Heart repair:  Scientists envision the use to cord blood stem cells to repair defective heart valves in babies and as an effective way to treat damaged heart muscle in heart attack victims.
  • Traumatic brain injury:  A U.S. Food & Drug Administration approved study has been launched to use a child's own stored umbilical cord blood in the treatment of traumatic brain injury.  Research elsewhere in the world is examining the usefulness of stem cells to treat victims of stroke.
  • Bone repair:  Scientists are examining the use of tissue-engineered bone, made with the use of cord blood stem cells, in regenerative medicine focused on bone repair.  U.S. scientists have created a tissue-engineered jaw bone.
  • Spinal cord injury:  Stem cells from a human newborn umbilical cord have been shown to improve the function of laboratory rats after an acute spinal cord injury, showing  significant improvement in mobility and cognitive function.  Scientists worldwide are studying the potential use of cord blood stem cells for nerve repair.
  • Hearing loss:  Cord blood stem cells are being studied by scientists for the treatment of hearing impairment.  Animals which have been treated with these stem cells have shown significant healing in the inner ear.
  • Diabetes, Parkinson's Disease, Cerebral Palsy, Cystic Fibrosis, Alzheimer's:  Laboratory, animal and other research is ongoing in developing treatments using umbilical cord blood stem cells in the treatment of these diseases, all of which are presently incurable.

"We believe that as research continues, and a breakthrough is made in one or more of these disease states, the value of storing umbilical cord blood stem cells at birth will increase exponentially," Dr. O'Neill said.  "Based on the research results to date, we believe that day is sooner rather than later."

About Cord Blood America

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.

CONTACT:

Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 19, 2011
2. China Cord Blood Corporation Files Its Annual Report on Form 20-F
3. Engineers use short ultrasound pulses to reach neurons through blood-brain barrier
4. New Study Finds Cord Blood-derived Stem Cell Treatments Improve Ataxia Patients Functionality and Quality of Life
5. QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers
6. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2012
7. Cord Blood America Enters Agreement With BancoVida, a Cord Blood Collection Company in San Juan, Puerto Rico
8. China Cord Blood Corporation to Report First Quarter Fiscal 2012 Financial Results
9. Cord Blood America Enters Agreement With Premera Blue Cross to Offer Member Discount on Stem Cell Collection Services
10. Cord Blood America Six Month Revenues Up 61 Percent; Gross Profit Up 100 Percent
11. Restoring blood flow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... PatientCrossroads announces that ... secure online PatientCrossroads platform, has exceeded both its one-year and overall recruitment goals ... study, which seeks to advance understanding of the hereditary risks for certain kinds ...
(Date:2/10/2016)... ... February 10, 2016 , ... Cenna Bioscience Inc., an emerging biopharmaceutical company focused ... announced today it has been selected to present at the Cavendish Global Health Impact ... Florida. The purpose of the Forum is to help family offices and foundations ...
(Date:2/9/2016)... , Feb. 9, 2016  Regenicin, Inc. (OTC ... specializing in the development and commercialization of regenerative ... tissues and organs, recently reported the Company,s operating ... quarter of 2016. Lonza America , ... 2015 fiscal year in the process of consummating ...
(Date:2/9/2016)... ... 2016 , ... Clinovo , the cloud-based eClinical software ... Capture (EDC) system ClinCaptureand its new Contract Research Organization (CRO) Partner Program ... San Mateo, California on February 10th and 11th. Watch 2-min video . ...
Breaking Biology Technology:
(Date:2/9/2016)... (NASDAQ: AWRE ), a leading supplier of biometrics software and ... ended December 31, 2015.  --> ... million, an increase of 61% compared to $4.3 million in the ... 2015 was $2.6 million compared to $0.2 million in the fourth ... Higher revenue and operating income in the fourth quarter of ...
(Date:2/3/2016)... -- --> --> Fourth quarter 2015: ... 1,187% compared with fourth quarter of 2014. Gross margin was ... 30.0). Earnings per share increased to SEK 6.39 (loss: 0.49). ... 74.7). , --> --> ... M (233.6), up 1,142% compared with 2014. Gross margin was ...
(Date:2/2/2016)... 2016 This BCC Research report provides ... reviewing the recent advances in high throughput ‘omic ... field forward. Includes forecast through 2019. ... and opportunities that exist in the bioinformatic market. ... as well as IT and bioinformatics service providers. ...
Breaking Biology News(10 mins):